Afyonkarahisar Merkez

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study. This trial focuses on patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study aims to assess how AZD0780 compares to placebo in reducing the risk of major adverse cardiovascular events, also known as MACE-PLUS, over the course of the trial. Participants are randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study continues until a primary analysis censoring date, which may be up to approximately 54 months from randomization. After this, a study closure visit will be conducted as the final visit for each participant. During the study, participants will be regularly monitored for cardiovascular events including heart attacks, strokes, urgent coronary revascularizations, and other related outcomes. Researchers will track the time to first occurrence of these events as the primary outcome. Safety and other secondary outcomes like all-cause mortality will also be assessed. The total participation time can last up to about 54 months, with ongoing evaluations throughout this period.

Researchers are evaluating the safety and effects of a new medicine called NNC0487-0111 in people who have Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF and excess body weight. This phase 3 clinical trial aims to find out if NNC0487-0111 is safe and effective for treating these conditions compared to a placebo. Participants have HFpEF or HFmrEF and a body mass index of 30 or above. The study is sponsored by Novo Nordisk AS and uses a randomized, quadruple-masked design. Participants will receive either NNC0487-0111 or a matching placebo by injection under the skin once a week. The NNC0487-0111 is given in increasing doses over time. The study is parallel in design, meaning participants are randomly assigned to one of the two groups and receive that treatment throughout the trial. This treatment period extends for up to about 165 weeks. The study evaluates the time to certain heart failure events, hospitalizations, cardiovascular deaths, and other major cardiovascular events. During the study, participants will be monitored regularly to assess heart failure outcomes and kidney function, as well as quality of life using questionnaires like the Kansas City Cardiomyopathy Questionnaire. Safety and effectiveness are assessed through hospital visits, heart failure event tracking, and blood tests including kidney function and blood sugar levels. The total participation spans over three years, with ongoing evaluations to measure the time to heart failure events and cardiovascular outcomes. Participants receive close medical monitoring throughout the study period.

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.

Researchers are evaluating orforglipron to measure its effects on cardiovascular outcomes in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This phase 3 study aims to compare orforglipron with a placebo to better understand its impact on major cardiovascular events over about five years. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally along with standard care. The study is double-blinded, meaning neither participants nor researchers will know who receives the active drug or placebo during the trial period. During the study, participants will be followed for around five years, with researchers monitoring the time to the first major cardiovascular event and additional outcomes such as cardiovascular and kidney events, changes in kidney function measured by eGFR, and the onset of type 2 diabetes. The study includes regular assessments to track these outcomes and ensure participant safety throughout the long-term follow-up.

Researchers are evaluating whether the combination of vicadrostat BI 690517 and empagliflozin helps adults with heart failure who have symptoms and a left ventricular ejection fraction LVEF of 40% or more. This phase III study is designed to compare the effects of vicadrostatempagliflozin tablets versus placeboempagliflozin tablets on heart failure outcomes. The study aims to understand if this combined treatment improves health and reduces heart-related events. Participants are randomly assigned to one of two groups one group takes vicadrostat plus empagliflozin tablets once a day, and the other takes placebo plus empagliflozin tablets once a day. The study has no fixed duration and continues as long as participants benefit and tolerate the treatment. Throughout the study, participants visit their doctors regularly for health checks, and study staff may also contact them by phone to monitor well-being and any side effects. During the study, researchers monitor participants health through regular doctor visits and phone contacts. They collect data on heart-related events such as cardiovascular death, hospitalizations for heart failure, and urgent visits for heart failure over up to 42 months. Participants also answer questions about their symptoms and well-being. The study carefully tracks safety and treatment tolerance while gathering information to determine if the combined treatment helps people with heart failure.

Researchers are evaluating ziltivekimab, a new medicine not yet approved anywhere, to see if it can help people who were hospitalized due to a heart attack. The study aims to find out if ziltivekimab can reduce the development of heart disease and prevent future heart attacks or strokes. This is a Phase 3 clinical trial comparing ziltivekimab to a placebo in patients with acute myocardial infarction. Participants will receive an initial loading dose of ziltivekimab or matching placebo by injection under the skin as soon as possible after an invasive heart procedure, within 36 hours for STEMI or 48 hours for NSTEMI patients. After the loading dose, they will get monthly injections of the same study medicine for up to two years, in addition to their standard care. During the study, participants will be monitored for major cardiovascular events such as heart attack, stroke, and cardiovascular death. Researchers will also track other heart-related outcomes and safety measures over a period of up to 25 months. The study involves regular visits for injections, assessments, and laboratory tests to evaluate the medicines effects and patient health throughout the trial.

This research aims to explore the added benefits of deep, slow breathing exercises and suboccipital relaxation, alongside routine physiotherapy and rehabilitation, on autonomic, motor, cognitive, and emotional functions in people who have experienced a stroke. The study compares these combined approaches to routine physiotherapy alone, addressing a gap in current stroke rehabilitation methods. It seeks to provide new scientific evidence to improve recovery and reduce the impact of stroke globally. Participants are divided into three groups one group performs deep breathing exercises in addition to standard rehabilitation, another receives suboccipital relaxation alongside routine therapy, and a control group receives only the routine physiotherapy program. Both interventions last 6 weeks, with sessions three times per week. Deep breathing sessions involve guided breathing cycles while lying down, and suboccipital release includes a hands-on technique performed by a practitioner. The routine program includes gait, balance, and upper limb training. Throughout the study, participants will undergo assessments before and after the 6-week intervention period. These include measurements of heart rate variability, balance, motor activity, upper limb function, cognitive ability, and depression levels. The study monitors these outcomes to evaluate the effects of the interventions, with safety and adherence overseen by the research team. The total participation time corresponds to the 6-week intervention duration.

Carpal tunnel syndrome CTS is a common nerve compression condition causing numbness, tingling, muscle weakness, and hand atrophy. This research aims to compare the effects of rest splints and high-intensity laser therapy HILT combined with physical therapy programs on pain, function, nerve conduction, and grip strength for patients with CTS. The study is designed as a prospective randomized controlled trial to better understand these treatments impacts on CTS symptoms and nerve function. Participants are divided into three groups. The first group receives a physical therapy program including wrist range of motion, strengthening, stretching, desensitization, tendon and nerve gliding exercises, and use of a resting splint for 6 weeks, five days a week 30 sessions total. The second group receives the same physical therapy plus high-intensity laser therapy over the carpal tunnel region daily for 6 weeks. The third group also follows the physical therapy program but receives a sham laser treatment mimicking the HILT without active laser emission to serve as a control. During the study, participants undergo assessments at baseline, after 6 weeks of treatment, and again at 12 weeks to measure pain using a Visual Analog Scale and other outcomes like function, sleep quality, neuropathic pain, nerve conduction studies, and grip strength. These evaluations include questionnaires, nerve tests, and strength measurements. The trial monitors participants progress and treatment effects over time to determine the comparative benefits of rest splints and HILT when combined with physical therapy.

Carpal tunnel syndrome CTS is the most common type of nerve compression disorder, causing symptoms like numbness, tingling, pain, and weakness in the hand areas served by the median nerve. This research compares two treatments for people with mild to severe CTS an ultrasound-guided injection around the median nerve and a traditional minimal incision surgery to relieve pressure on the nerve. The study aims to evaluate which approach better reduces symptoms and improves hand function. The study involves two treatment groups. One group will receive a minimal incision surgery where a small cut is made to relieve pressure on the median nerve by cutting the surrounding tissue. The other group will have an ultrasound-guided injection of 5 cc of 5% dextrose around the median nerve using a precise technique to reduce risk of injury. Both treatments target the same nerve but use different methods to reduce compression. Participants will be monitored throughout the study with assessments of wrist pain using a visual analog scale VAS at 4 and 12 weeks after treatment. Additional measurements include symptom questionnaires, nerve size by ultrasound, electrical nerve tests, and hand grip strength at the same time points. The study will track changes from baseline to understand each treatments impact on symptoms and nerve function over about three months.

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. The study aims to assess whether this combination can help reduce cardiovascular risks compared to a placebo with empagliflozin. This Phase III trial involves adults with these conditions who are already receiving treatment for them. Participants are randomly assigned to one of two groups. One group takes vicadrostat and empagliflozin tablets daily, while the other group takes placebo tablets that look like vicadrostat but have no active medicine, alongside empagliflozin. Treatment lasts from two and a half years up to four years and three months. All participants continue their usual medications for diabetes, blood pressure, and heart disease during the study. Throughout the study, lasting up to four years and three months, participants visit the study site regularly for health checks and blood samples. Doctors monitor cardiovascular events and any side effects experienced. The main outcome measured is the time until the first cardiovascular death or heart failure event. Other health indicators like blood pressure and kidney function are also tracked to understand the effects of the treatment combination.